A detailed history of Sugar Maple Asset Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Sugar Maple Asset Management, LLC holds 1,000 shares of LCTX stock, worth $630. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Holding current value
$630
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 16, 2025

BUY
$0.5 - $0.95 $500 - $950
1,000 New
1,000 $0

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $107M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Sugar Maple Asset Management, LLC Portfolio

Follow Sugar Maple Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sugar Maple Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sugar Maple Asset Management, LLC with notifications on news.